Selecting here opens the current stored cards. The pinned link below records their fingerprints. Do not enter patient information in links or searches.
Share or print this source review
1 local source card selected. Local card fingerprints checked where supplied. This is not an original-document hash, source-currency guarantee or clinical approval. Record-level cautions below are the current library's cautions, not a frozen prior version.
Copy is optional; the link can be selected and copied manually. No patient data or dose decision is collected.
Clinical context remains essential
Independent clinical review is pending. Confirm indication, exact formulation/route, population, renal measure and units, kidney-function stability, dialysis prescription, interacting drugs, monitoring and source revision. An RX mirror and its original label are not independent corroboration. Missing disagreement notes do not certify agreement.
An RX mirror and its underlying label are not independent clinical confirmations.
Check source scope before reading a dose
OZEMPIC: selected primary-label renal guidance and limits
Product / population
Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.
Renal method
Qualitative renal categories including kidney failure; no new renal threshold
Source revision
Revision date not captured in selected review; retrieval date is not revision date.
Retrieved
2026-11-07
Local review status
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Documented differences and cautions on this drug
All record notes are retained here, including notes about sources not selected in this review.
OZEMPIC: source applicability and renal evidence limits
Baseline no-adjustment guidance and volume-depletion AKI warnings address different questions. Retain both; do not substitute another semaglutide formulation or brand.
What to reconcile: Monitor kidney function with volume-depleting reactions, especially during initiation/escalation.
DailyMed / product prescribing information · Adult OZEMPIC subcutaneous injection for its labeled indications; not oral semaglutide or another semaglutide brand/regimen.
Renal method: Qualitative renal categories including kidney failure; no new renal threshold Source date: Revision date not captured in selected review; retrieval date is not revision date. Retrieved: 2026-11-07
Qualified no-adjustment statement. Apply only to the population, product and renal range described in this source.
Before using this finding
Kidney-failure PK evidence is not a modality-specific dialysis schedule.
Dialysis evidence: No dialysis regimen established in selected content
Selected sections checked against the identified source; not a complete monograph or independent clinician approval.
Sections 8.6 and 5.6
No dose adjustment is recommended for renal impairment, including kidney failure in the supporting PK evidence. Monitor renal function when adverse reactions can cause volume depletion, especially during initiation or escalation. The no-adjustment statement does not eliminate dehydration-related AKI risk or establish interchangeable dosing across semaglutide products.
RDM72-semaglutide-ozempic-label-1 · Source locator: Sections 8.6 and 5.6
Source-specific limits
Selected renal section, not a complete prescribing monograph. A label and its mirror are not independent evidence.
This reference does not select a regimen. Complete the indication, measured/estimated renal function and trend, dialysis setting, source rationale, monitoring and reassessment plan in your institution's approved documentation system. Confirm the complete current source before adopting its regimen.
GlobalRPh Renal Dosing Master v7.4. Review the retrieval and revision dates attached to each source. Selecting a reference does not imply clinical verification.
